{"url_path":"/sec/lbrx/8-k/2026-07-22/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1691082/0001193125-26-311357-index.html","accession_number":"0001193125-26-311357","cik":"0001691082","ticker":"LBRX","issuer_name":"LB PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1691082/0001193125-26-311357-index.html","primary_entity_key":"0001691082","primary_entity_name":"LB PHARMACEUTICALS INC"},"word_count":64,"has_tables":true,"body_markdown":"Item 8.01\n\nOther Events.\n\nOn July 22, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and, other than the quotes contained therein, is incorporated herein by reference."}